Tylki-Szymanska A, Berger J, Löschl B, Lugowska A, Molzer B
Instytut Pomnik Centrum Zdrowia Dziecka, Warsaw, Poland.
Clin Genet. 1996 Nov;50(5):287-92. doi: 10.1111/j.1399-0004.1996.tb02376.x.
Metachromatic leukodystrophy (MLD) is an autosomal, recessively inherited, lysosomal storage disease caused by arylsulfatase A (ASA) activity deficit. Arylsulfatase A initiates the degradation of sulfatide (cerebroside sulfate), which is an essential component of myelin. The main clinical symptoms are caused by progressive demyelination. At least 34 MLD-related ASA mutations are known to date. I179S (E3P799) is a disease-related mutation, described for the first time by Fluharty in 1991. This aberration appears to substantially reduce, but not completely eliminate ASA activity, and was detected in individuals with late-onset (juvenile or adult) forms of MLD. This paper deals with the peculiar clinical course in three unrelated juveniles with late-onset MLD carrying the I179S mutations on one allele. In the three described patients with the I179S mutation, psychiatric disturbances and intellectual impairment dominated the clinical picture, while the neurological lesions progressed more slowly. Although the symptoms appeared rather early, making it possible to classify this as the juvenile type of MLD, the clinical picture was more that of the adult type. Although the mutations on the second allele in our patients are unknown, one can speculate, that the mutation I179S plays an important role in the characteristic clinical course (psychiatric impairment, slower neurological deterioration, but relatively early onset). It seems that I179S mutation on one allele with another mutation on the other allele reduces ASA activity, but the enzyme can still cope with a part of the substrate influx, leading to late-juvenile-onset MLD with such strikingly similar phenotypes remaining a little bit of the adult (psychiatric) type. This could be one more argument in favour of phenotype-genotype correlation in patients with MLD.
异染性脑白质营养不良(MLD)是一种常染色体隐性遗传的溶酶体贮积病,由芳基硫酸酯酶A(ASA)活性缺乏引起。芳基硫酸酯酶A启动硫脂(脑硫脂)的降解,而硫脂是髓磷脂的重要组成部分。主要临床症状由进行性脱髓鞘引起。迄今为止,已知至少有34种与MLD相关的ASA突变。I179S(E3P799)是一种与疾病相关的突变,由弗卢哈蒂于1991年首次描述。这种畸变似乎会大幅降低但不会完全消除ASA活性,在迟发型(青少年或成人)MLD患者中被检测到。本文探讨了三名携带I179S突变一个等位基因的无关青少年迟发型MLD患者的特殊临床病程。在所描述的三名I179S突变患者中,精神障碍和智力损害在临床表现中占主导地位,而神经病变进展较为缓慢。尽管症状出现得相当早,使其有可能被归类为青少年型MLD,但临床表现更像是成人型。虽然我们患者第二个等位基因上的突变未知,但可以推测,I179S突变在特征性临床病程(精神损害、神经功能恶化较慢但发病相对较早)中起重要作用。似乎一个等位基因上的I179S突变与另一个等位基因上的另一个突变会降低ASA活性,但该酶仍能应对部分底物流入,导致青少年晚期发病的MLD,其具有如此惊人相似的表型,仍带有一点成人(精神)型的特征。这可能是支持MLD患者表型 - 基因型相关性的又一个论据。